| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
41,630,000 |
| Market
Cap: |
26.95(M) |
| Last
Volume: |
204,752 |
Avg
Vol: |
423,645 |
| 52
Week Range: |
$0.6474 - $0.6474 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lannett primarily develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. Co.'s primary products include: Amphetamine IR Tablets, which are used to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy; Amphetamine ER Capsules, which are indicated for use to treat ADHD; Dicyclomine Tablets, which are indication for the treatment of functional bowel disorder and irritable bowel syndrome; Fluphenazine Tablets, which are used for the management of manifestations of psychotic disorders; and Levothyroxine Capsules, which are soft gel capsules used to treat patients with hypothyroidism and other conditions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
166,159 |
| Total Buy Value |
$0 |
$0 |
$0 |
$81,668 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Landis G. Michael |
Principal Accounting Officer |
• – – |
2016-09-15 |
4 |
S |
$32.30 |
$139,988 |
D/D |
(4,334) |
2,127 |
|
- |
|
| Landis G. Michael |
Principal Accounting Officer |
• – – |
2016-09-15 |
4 |
OE |
$13.86 |
$60,069 |
D/D |
4,334 |
6,461 |
|
- |
|
| Bedrosian Arthur P |
CEO |
• • – |
2016-09-09 |
4 |
OE |
$4.03 |
$442,289 |
D/D |
95,325 |
675,558 |
|
- |
|
| Bedrosian Arthur P |
CEO |
• • – |
2016-09-09 |
4 |
D |
$30.42 |
$1,153,891 |
D/D |
(37,932) |
650,745 |
|
- |
|
| Maher James M. |
Director |
– • – |
2016-09-01 |
4 |
AS |
$33.91 |
$50,119 |
D/D |
(1,478) |
20,320 |
|
- |
|
| Landis G. Michael |
Principal Accounting Officer |
• – – |
2016-08-31 |
4 |
S |
$33.40 |
$226,716 |
D/D |
(6,786) |
2,127 |
|
- |
|
| Landis G. Michael |
Principal Accounting Officer |
• – – |
2016-08-31 |
4 |
OE |
$4.16 |
$68,375 |
D/D |
6,333 |
6,913 |
|
- |
|
| Bedrosian Arthur P |
CEO |
• • – |
2016-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,718 |
618,165 |
|
- |
|
| Galvan Martin P |
VP of Finance & CFO |
• – – |
2016-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,609 |
38,370 |
|
- |
|
| Smith Kevin |
VP of Sales and Marketing |
• – – |
2016-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,428 |
16,498 |
|
- |
|
| Ehlinger Robert |
VP and CIO |
• – – |
2016-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
881 |
19,861 |
|
- |
|
| Dedhiya Mahendra |
Chief Scientific Affairs |
• – – |
2016-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
870 |
2,976 |
|
- |
|
| Landis G. Michael |
Principal Accounting Officer |
• – – |
2016-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,173 |
2,580 |
|
- |
|
| Abt John |
Vice President of Quality |
• – – |
2016-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,050 |
6,110 |
|
- |
|
| Smith Kevin |
VP of Sales and Marketing |
• – – |
2016-07-23 |
4 |
D |
$30.67 |
$25,180 |
D/D |
(821) |
15,070 |
|
- |
|
| Galvan Martin P |
VP of Finance & CFO |
• – – |
2016-07-23 |
4 |
D |
$30.67 |
$26,070 |
D/D |
(850) |
36,761 |
|
- |
|
| Landis G. Michael |
Principal Accounting Officer |
• – – |
2016-07-23 |
4 |
D |
$30.67 |
$1,595 |
D/D |
(52) |
1,407 |
|
- |
|
| Bedrosian Arthur P |
CEO |
• • – |
2016-07-23 |
4 |
D |
$30.67 |
$75,172 |
D/D |
(2,451) |
614,447 |
|
- |
|
| Smith Kevin |
VP of Sales and Marketing |
• – – |
2016-07-22 |
4 |
D |
$30.67 |
$9,906 |
D/D |
(323) |
15,891 |
|
- |
|
| Abt John |
Vice President of Quality |
• – – |
2016-07-22 |
4 |
D |
$30.67 |
$3,006 |
D/D |
(98) |
5,060 |
|
- |
|
| Galvan Martin P |
VP of Finance & CFO |
• – – |
2016-07-22 |
4 |
D |
$30.67 |
$14,047 |
D/D |
(458) |
37,611 |
|
- |
|
| Ehlinger Robert |
VP and CIO |
• – – |
2016-07-22 |
4 |
D |
$30.67 |
$16,010 |
D/D |
(522) |
18,980 |
|
- |
|
| Landis G. Michael |
Principal Accounting Officer |
• – – |
2016-07-22 |
4 |
D |
$30.67 |
$4,723 |
D/D |
(154) |
1,459 |
|
- |
|
| Bedrosian Arthur P |
CEO |
• • – |
2016-07-22 |
4 |
D |
$30.67 |
$32,909 |
D/D |
(1,073) |
616,898 |
|
- |
|
| Drabik David A |
Director |
– • – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,075 |
24,575 |
|
- |
|
762 Records found
|
|
Page 14 of 31 |
|
|
